c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma - Wikidata - wikimedia - TriplyDB

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

http://www.wikidata.org/entity/Q39554370

about

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?The steady progress of targeted therapies, promising advances for lung cancer Genetics and biology of pancreatic ductal adenocarcinoma K-Ras protein as a drug target The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis Targeting pathways downstream of KRAS in lung adenocarcinoma.Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.Systems biology approaches to develop innovative strategies for lung cancer therapy.Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report.Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.Oncogenic KRAS signalling in pancreatic cancer.Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide.Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma Development of siRNA payloads to target KRAS-mutant cancer.Genetically engineered mouse models of PI3K signaling in breast cancer.Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors Drugging the undruggable RAS: Mission possible?Loss of RhoA Exacerbates, Rather Than Dampens, Oncogenic K-Ras Induced Lung Adenoma Formation in Mice.Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1.Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression.Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations Genetic and biochemical alterations in non-small cell lung cancer.Tissue-specific tumorigenesis: context matters.

P2860

Q24294914-61626843-E13A-4614-A5D2-29E79ED7B649 Q26744787-271EBC8A-9D2F-41D9-8ABC-020EB4CA84F0 Q26746895-1403E018-5E5D-48A6-9616-0085A7F35B97 Q26765438-439C9C3A-649C-4F0F-B400-78A10ACA7937 Q26766684-888B303C-12A2-4A60-88A2-1A1B35701D06 Q27021883-024DC30B-78BD-44C8-9A85-E4D75667C687 Q27026323-9EFA01FF-E658-4A13-8576-B7B94E02E322 Q27335279-D953F1B5-45FE-4DA9-80F5-F6577BB4AEAB Q27685364-B5528D36-7521-48AC-A9D9-3A0C6AE0D626 Q28079848-F1062A37-03F2-4E78-897F-A9BAABD8216D Q28260541-557B2856-99DB-4F5B-932E-3FDC13480453 Q28512744-5D7AE6F4-8902-4E50-82F4-3102F1174576 Q28543407-5DC6C3F8-6081-4F55-A55E-085974C7F94E Q28607006-B0BDFFCE-7219-4586-8F62-DBA6A63A8926 Q28818626-07C8A9DD-B827-4615-AA90-078D3468A253 Q30597330-AFAD4D2C-E5B6-4B75-A188-52EEBFEC53C2 Q33604228-FAD0E57E-FC8B-42C0-9E2E-7FB7A080617D Q33705675-131D6AF9-66E7-40EA-B8F2-7C1AE5C446B0 Q33720233-D9365BB0-7C61-4E57-9038-8BB2B05680E3 Q33843962-B4F2656F-6C97-43A1-A937-2B8F7DB0897B Q33971120-2374B1EA-62B0-43B3-9BD6-B9F752F3BB73 Q34113460-80D56D25-2A44-4998-BC4E-FD8442AECC20 Q34206164-3505800D-2EA1-450F-B030-3332292EC6F9 Q34246014-AF99B1D3-7B0A-4CD4-8753-29B309D9D9A0 Q34287993-98B24961-D859-4B3D-830F-BAA670A67ED6 Q34332175-C0A38E54-EBA9-4BBD-B77D-56964A677733 Q34409141-0B8D48E1-9707-4BD7-91AA-9CAF43340F00 Q34572036-3A8C9419-B04D-4949-B10F-34655432A1B2 Q35041937-5B6F0AEA-DD66-4E9D-99AC-8D09B31E7255 Q35163434-67512A85-4432-432C-8F0B-79849196C1B3 Q35648144-B69F7BFC-FC07-4987-8076-14C220A994CA Q35672193-206D86BB-1333-4FFA-94BB-BA5ED8B84E0B Q35693850-01A6B338-E11B-4B78-A779-2222B98AE793 Q35763729-3066D325-7EF1-47B0-9EF9-046BB2D0C0FC Q35791258-DE5A6676-22B5-4CAA-ADCC-27B2568F03F9 Q35904176-4A32659E-5DC8-46AB-9BBC-453E268E53C7 Q35904248-9E8AA251-B944-4A18-A42E-92378798045D Q35971891-014A5A22-B581-4820-8506-D0ECE85050B3 Q36184584-1129F611-9567-4F6A-9340-0F9D6AEDEC7A Q36296335-7A82668C-34A3-4216-AD08-52B3530035C8

P2860

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

http://www.wikidata.org/entity/Q39554370

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma

@en

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma.

@nl

type

label

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma

@en

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma.

@nl

prefLabel

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma

@en

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma.

@nl

P1433

Q39554370-4BC805D7-88DF-4916-B687-B4690FF5D665

P1476

Q39554370-CA99E5EE-F0E6-4420-8AEE-38DE2A6C5531

P2093

Q39554370-34FD7C2C-1512-4CAC-820C-8C41AE073E31

Q39554370-D444DABC-E73E-4E8B-BB5C-3A6BC4581763

Q39554370-E2F87BD7-A23C-4E73-9F3A-2647D292A759

Q39554370-F2164702-F7ED-43D6-A282-EEDE5D4F0F7C

Q39554370-F646702E-12B9-48CF-BB87-8E45F3BD8CCD

P2860

Q39554370-0289EDD4-8829-4843-A0CA-1112F83680BC

Q39554370-07239BA8-95C9-4B92-948A-7A478A9B2439

Q39554370-0945D0C9-754D-403F-82C5-AF9631430931

Q39554370-0BC61608-97D3-4D97-A1D0-A1AF3BBA06FD

Q39554370-0F35C3C3-9183-4D7D-942B-3E8334E16814

Q39554370-2549CEFF-F7CF-4015-91DC-F5C546B923DE

Q39554370-2E002745-7E53-4631-81F5-F8EA8BAB784D

Q39554370-318FE06C-0122-4C87-B30B-AEA6CA31F878

Q39554370-3383B2E0-E1F0-4845-A1DF-B7E25941C96A

Q39554370-3938C690-7EA8-43ED-8226-3FD178EEAB9A

P304

Q39554370-B7D31A17-FE34-4EAB-9E32-9589E9639A58

P31

Q39554370-643DFD09-46D5-4F35-95DE-C617C6E12071

P356

Q39554370-80954B35-2E61-43B0-B0D8-53BBFBF83F21

P433

Q39554370-C327B9BC-936A-48E8-9C57-2BC0B085C882

P478

Q39554370-BF741684-7563-407C-B492-45CF0E981F6A

P50

Q39554370-32D32C60-B02A-41C9-9D62-CB2099BB576E

Q39554370-6DF1D909-B891-408A-89F7-4E0C529D3771

Q39554370-C4530827-70A4-4136-B6D1-1A5E9AD247FA

P577

Q39554370-0AE6E610-0DBD-4B8F-BCA3-5BDD86C2FB1A

P5875

Q39554370-F48240E3-9959-4E4E-9C16-176224D71E62

P698

Q39554370-3C7F3C08-6AEA-4C7E-9395-0D47EC54FB63

P932

Q39554370-4C3B38E4-6AD2-40C4-A16F-64D16D49FCB5

P356

J.CCR.2011.04.002

P1433

P1476

c-Raf, but not B-Raf, is essen ...... non-small cell lung carcinoma

@en

P2093

David Santamaría

http://www.w3.org/2001/XMLSchema#string

Mariano Barbacid

http://www.w3.org/2001/XMLSchema#string

Marta Cañamero

http://www.w3.org/2001/XMLSchema#string

Pierre Dubus

http://www.w3.org/2001/XMLSchema#string

Rafael B Blasco

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

P304

652-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.04.002

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Manuela Baccarini

P577

2011-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51071316

http://www.w3.org/2001/XMLSchema#string

P698

21514245

http://www.w3.org/2001/XMLSchema#string

P932

4854330

http://www.w3.org/2001/XMLSchema#string